In line with the expanding use of medicinal cannabis in Australia, MIPS has seen a rise in claims and complaints related to medicinal cannabis prescribing, particularly in vertically integrated asynchronous telehealth settings. In this session, we’ll explore key risk areas and regulatory considerations, including:
- Non-compliance with Schedule 8 prescribing requirements, such as failing to check real-time prescription monitoring databases.
- Challenges of prescribing across state borders in a telehealth context.
- Prescribing excessive quantities.
- Inadequate patient assessment prior to prescribing.
- Failure to meet the Medical Board of Australia’s Telehealth Guidelines.
We’ll also discuss the challenges faced by practitioners managing patients who are prescribed medicinal cannabis by other providers.
Learning outcomes
By the end of this session, you will be able to:
- Discuss current legal and regulatory frameworks for prescribing medicinal cannabis in Australia.
- Discuss strategies for managing clinical interactions with patients who are being treated with medicinal cannabis.
- Identify key considerations and risks when prescribing medicinal cannabis or managing patients who are being prescribed medicinal cannabis elsewhere to ensure safe, compliant, and effective clinical practice.
MIPS resources
